Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

Alexander Lesokhin, Ruben Niesvizky, Bertrand Arnulf, Sarah Larson, Christopher Strouse, Carlos Fernandez de Larrea, David Vesole, Yuya Nagai, Sharon T. Sullivan, Eric Leip, Andrea Viqueira, Nizar Bahlis

Blood (2025) 146 (Supplement 1): 2269.

https://doi.org/10.1182/blood-2025-2269

Published: 2025

Journal Articles

Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group

Grzegorz Charlinski, Jacek Krzanowski, Dominik Gorzelak, Agata Tyczynska, Lukasz Szukalski, Magdalena Olszewska-Szopa, Pawel Steckiewicz, Sylwia Trzpiot, Agnieszka Druzd-Sitek, Jaroslaw Grzyb, Anna Kopinska, Agnieszka Szymczyk, Boguslaw Machalinski, Elzbieta Wiater, Michał Mielnik, Marek Rodzaj, Marek Hus, David Vesole, Artur Jurczyszyn

Blood (2025) 146 (Supplement 1): 5838.

https://doi.org/10.1182/blood-2025-5838

Published: 2025

Journal Articles

B- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy

Adam Albitar, Alfonso Lam, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David Vesole, Harsh Parmar, Andrew Pecora, Andrew Ip, Andre Goy, David Siegel, Maher Albitar

Blood (2025) 146 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2025-1754

Published: 2025

Journal Articles

Pomalidomide salvage in T-cell engager monotherapy failures: Real-world experience with talquetamab or elranatamab with pomalidomide combinations in heavily pretreated multiple myeloma

James Di Palma-Grisi, David Siegel, Noa Biran, Pooja Phull, David Vesole, Harsh Parmar

Blood (2025) 146 (Supplement 1): 2229.

https://doi.org/10.1182/blood-2025-2229

Published: 2025

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Alterations in the gut microbiome and the association of butyrate producers with progression-free survival in multiple myeloma patients undergoing autologous stem cell transplantation

Ariel Aptekmann, Enrique Corapi, Iriana Colorado, Reilly Kobbe, Joshua Zenreich, Adolfo Aleman, Aditya Kasina, Aloise Hynekamp, Pooja Phull, Harsh Parmar, David Vesole, Michele Donato, Noa Biran, David Siegel, Rena Feinman

Blood (2025) 146 (Supplement 1): 575.

https://doi.org/10.1182/blood-2025-575

Published: 2025

Journal Articles

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Blood (2014) 123 (12): 1826–1832.

https://doi.org/10.1182/blood-2013-11-538835

Published: 2014

Journal Articles

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach

Angela Baker, Esteban Braggio, Susanna Jacobus, Sungwon Jung, Dirk Larson, Terry Therneau, Angela Dispenzieri, Scott A. Van Wier, Gregory Ahmann, Joan Levy, Louise Perkins, Seungchan Kim, Kimberly Henderson, David Vesole, S. Vincent Rajkumar, Diane F. Jelinek, John Carpten, Rafael Fonseca

Blood (2013) 121 (16): 3147–3152.

https://doi.org/10.1182/blood-2012-07-443606

Published: 2013

Includes: Supplemental data

Journal Articles

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Blood (2011) 117 (18): 4691–4695.

https://doi.org/10.1182/blood-2010-10-299487

Published: 2011

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.

Anuj Mahindra, MD, David Vesole, MD, PhD, Matt E. Kalaycio, MD, Jorge Vela-Ojeda, MD, Smriti Shrestha, MS, MA, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Gustavo A. Milone, MD, Sagar Lonial, MD, Parameswaran N. Hari, MD, MS

Blood (2009) 114 (22): 532.

https://doi.org/10.1182/blood.V114.22.532.532

Published: 2009

Journal Articles

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Blood (2009) 114 (22): 1218.

https://doi.org/10.1182/blood.V114.22.1218.1218

Published: 2009

Journal Articles

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Blood (2009) 114 (9): 1729–1735.

https://doi.org/10.1182/blood-2009-04-205013

Published: 2009

Journal Articles

Therapy Related Leukemia in HIV Patients after Treatment for Non-Hodgkin Lymphoma

Jed Katzel, MD, Sanford Kempin, MD, David Vesole, MD, Portia Lagmay-Fuentes, NP, William Cook, MD, Frederick Siegal

Blood (2008) 112 (11): 5284.

https://doi.org/10.1182/blood.V112.11.5284.5284

Published: 2008

Journal Articles

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

Kavita M. Dhodapkar, Scott Barbuto, Phillip Matthews, Anjli Kukreja, Amitabha Mazumder, David Vesole, Sundar Jagannath, Madhav V. Dhodapkar

Blood (2008) 112 (7): 2878–2885.

https://doi.org/10.1182/blood-2008-03-143222

Published: 2008

Includes: Supplemental data

Journal Articles

Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

Amitabha Mazumder, MD, Jonathan Kaufman, MD, Sagar Lonial, MD, Sundar Jagannath, MD, David Vesole, MD, PhD

Blood (2007) 110 (11): 3612.

https://doi.org/10.1182/blood.V110.11.3612.3612

Published: 2007

Journal Articles

Current Staging Systems Are Inadequate Predictors of Treatment Failure after Autologous Hematopoietic Stem Cell Transplants (AuHCT) in Multiple Myeloma (MM).

Parameswaran Hari, MD, Waleska Pérez, MPH, Mei-Jie Zhang, PhD, Christopher Bredeson, MD, MSc, Gustavo Milone, MD, Donna Reece, MD, Vivek Roy, MD, David Vesole, MD, PhD

Blood (2007) 110 (11): 938.

https://doi.org/10.1182/blood.V110.11.938.938

Published: 2007

Journal Articles

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, PhD, Michael Williams, MD, Rafat Abonour, MD, David Siegel, MD, Philip Greipp, MD

Blood (2007) 110 (11): 74.

https://doi.org/10.1182/blood.V110.11.74.74

Published: 2007

Journal Articles

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

David Siegel, MD, PhD, Sundar Jagannath, MD, Amitabha Mazumder, MD, David Vesole, MD, Ivan Borrello, MD, Jens Sydor, PhD, Jim Wright, PhD, Jon Patterson, BS, Emmanuel Normant, PhD, Julian Adams, PhD, Kenneth Anderson, MD, David Grayzel, MD, Paul Richardson, MD

Blood (2006) 108 (11): 3579.

https://doi.org/10.1182/blood.V108.11.3579.3579

Published: 2006

Journal Articles

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, Philip Greipp, MD

Blood (2006) 108 (11): 799.

https://doi.org/10.1182/blood.V108.11.799.799

Published: 2006

Journal Articles

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Angela Dispenzieri, MD, Emily Blood, MS, David Vesole, MD, Rafael Fonseca, MD, Natalie Callander, MD, Philip R. Greipp, MD

Blood (2005) 106 (11): 2546.

https://doi.org/10.1182/blood.V106.11.2546.2546

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group

B- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy

Pomalidomide salvage in T-cell engager monotherapy failures: Real-world experience with talquetamab or elranatamab with pomalidomide combinations in heavily pretreated multiple myeloma

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Alterations in the gut microbiome and the association of butyrate producers with progression-free survival in multiple myeloma patients undergoing autologous stem cell transplantation

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Therapy Related Leukemia in HIV Patients after Treatment for Non-Hodgkin Lymphoma

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

Current Staging Systems Are Inadequate Predictors of Treatment Failure after Autologous Hematopoietic Stem Cell Transplants (AuHCT) in Multiple Myeloma (MM).

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only